ANAPTYSBIO, INC. (NASDAQ:ANAB) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On May11, 2017, AnaptysBio, Inc.
(AnaptysBio) issued a press release
announcing its financial results for the three months ended
March31, 2017. A copy of the press release is attached as
Exhibit99.01 to this Current Report on Form8-K.
The information in this Item2.02, including Exhibit 99.01 to this
Current Report on Form 8-K, shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section
or Sections11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained in this Item2.02 and in the
accompanying Exhibit 99.01 shall not be incorporated by reference
into any registration statement or other document filed by
AnaptysBio with the Securities and Exchange Commission, whether
made before or after the date of this Current Report on Form 8-K,
regardless of any general incorporation language in such filing
(or any reference to this Current Report on Form 8-K generally),
except as shall be expressly set forth by specific reference in
such filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits.
| 99.01 |
Press release issued by AnaptysBio regarding its financial results for the three months ended March31, 2017, dated May11, 2017. |
About ANAPTYSBIO, INC. (NASDAQ:ANAB)
AnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company’s ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP). ANAPTYSBIO, INC. (NASDAQ:ANAB) Recent Trading Information
ANAPTYSBIO, INC. (NASDAQ:ANAB) closed its last trading session up +1.04 at 26.68 with 98,752 shares trading hands.
